ImmunityBio Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy platforms, alone and together, act to drive an immune response with the goal of creating durable immune memory generating safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA ® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Current Price
$7.97
-2.21%GoodMoat Value
$0.66
91.7% overvaluedProfile
Valuation (TTM)
Market Cap$8.19B
P/E-9.59
EV—
P/B—
Shares Out1.03B
P/Sales58.12
Revenue$140.98M
EV/EBITDA—
ImmunityBio Inc (IBRX) Stock Analysis
Market Cap$8.19B
Current Price$7.97
P/E Ratio-9.59
Forward P/E—
PEG Ratio-0.03
EPS$-0.38
Book Value$-0.49
P/B Ratio—
IBRX Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Debt: 754M
Revenue
2M
FY19
—
FY20
—
FY21
—
FY22
—
FY23
15M
FY24
113M
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
IBRX 52-Week Range
$1.98
$11.55
50-Day MA: $7.78200-Day MA: $4.56
Did you know?
Trading 92% above its estimated fair value of $0.66.
ImmunityBio Inc (IBRX) Financial Summary
ImmunityBio Inc (IBRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $7.97 with a market capitalization of $8.19B.
Key valuation metrics include a P/E ratio of -9.59, and EPS of $-0.38. The company reports a profit margin of -606.2%.
IBRX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $8.19B |
| P/E Ratio | -9.59 |
| EPS | $-0.38 |
| P/S Ratio | 58.12 |
| Profit Margin | -606.2% |
IBRX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $2.20M | $-157.78M |
| FY20 | $605000.00 | $-221.85M |
| FY21 | $934000.00 | $-346.79M |
| FY22 | $240000.00 | $-416.57M |
| FY23 | $622000.00 | $-583.20M |
| FY24 | $14.74M | $-413.56M |
| FY25 | $113.29M | $-351.40M |
ImmunityBio Inc (IBRX) Valuation
Based on GoodMoat's DCF model, ImmunityBio Inc has a fair value estimate of $0.66. At the current price of $7.97, the stock appears 1101.4% overvalued relative to our intrinsic value estimate.
IBRX Quality Indicators
ImmunityBio Inc maintains a profit margin of -606.2% and an operating margin of -226.0%. The current ratio is 5.10.
About ImmunityBio Inc
ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy platforms, alone and together, act to drive an immune response with the goal of creating durable immune memory generating safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA ® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
IBRX Free Cash Flow
ImmunityBio Inc generated $-309.19M in trailing twelve-month free cash flow, representing an FCF yield of -3.77%. This low FCF yield may reflect heavy reinvestment or growth spending.
IBRX Shares Outstanding
ImmunityBio Inc has 1.03 billion shares outstanding at a share price of $7.97, giving it a market capitalization of $8.19B.